2025 Report to the Community - Flipbook - Page 16
Innovating Patient Care
National report reveals
BMT program at
MUSC one of only 12
centers performing
better than expected
The Medical University of South Carolina Blood and Marrow
Transplant Program’s outcomes for one-year survival for
allogeneic transplant are above the expected survival rate,
compared with similar patient transplants across the U.S.
The Center for International Blood and Marrow Transplant
Research (CIBMTR) recently released its annual report
on 172 centers across the country that perform blood
and bone marrow transplants. Allogeneic transplants
involve transplanting a donor’s stem cells into a patient as a
treatment for blood cancers, sickle cell disease, bone marrow
failure syndromes and more.
CIBMTR calculates each BMT program’s expected oneyear survival rate based on that program’s patients, taking
into account a variety of factors, including age, co-existing
diseases, donor type, disease stage and more. Centers are
then rated as underperforming, performing as predicted or
overperforming.
MUSC was one of only 12 out of 172 centers across the U.S.
that performed better than expected during the evaluation
years of 2020 through 2022.
The MUSC program is also one of the few combined adult/
pediatric programs. The adult program, under the umbrella
of MUSC Hollings Cancer Center, primarily treats people
with blood cancers while the pediatric program, as part of
MUSC Children’s Health, treats children with cancer, sickle
cell disease, immunodeficiencies and more.
14
MUSC Hollings Cancer Center
